A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)

Status

Active (Recruiting)

Disease

Stage I adenocarcinoma non-small cell lung cancer (NSCLC)

Treament Agent

Datopotamab Deructecan (Dato-DXd) + Rilvegostomig

Study Phase

Phase III

Resources and Links

https://www.astrazenecaclinicaltrials.com/study/D926TC00001/

Physician Name(s)

Dr John Low Seng Hooi

Description

The primary objective of the study is to assess the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig relative to SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.

Cancer Type

Lung Cancer

I would like to be a part of tomorrow's breakthrough

Clinical trials are part of research studies involving patient volunteers that are conducted to find safe and effective treatments for a variety of health conditions. They are critical to the advancement of medicine and improving patient health. Participating in clinical trials offers patients the opportunity to try new and effective treatments that could potentially improve their condition while taking part in vital research that can benefit many future patients.

In Pantai Hospital Kuala Lumpur, clinical trials are carried out under our Clinical Research team.

If you would like to participate in any of our clinical trials or would like to know, please provide your information below and we will be in touch with you: